Samsung Biologics to Set Up Independent Booth at Bio Japan 2025

First Independent Booth Operation
Expanding Order Acquisition Targets Beyond the Top 20 to the Top 40 Pharmaceutical Companies

Samsung Biologics announced on September 30 that it will participate in "Bio Japan 2025," Asia's largest bio and pharmaceutical exhibition, to be held in Yokohama, Japan, from October 8 to 10.

Bio Japan 2025 Samsung Biologics Booth. Samsung Biologics

Bio Japan, organized by the Japan Bioindustry Association, is a leading Asian exhibition that began in 1986. The event now covers the entire bio industry, including biopharmaceuticals, regenerative medicine, digital healthcare, and health functional foods, and continues to expand in scale. This year, a total of 1,139 companies and more than 18,000 participants are expected to attend and actively engage in business meetings.

Samsung Biologics, participating for the third consecutive year since 2023, will set up its own independent booth for the first time this year to pursue more proactive order acquisition activities. In particular, the company aims to further expand its market share among the global top 20 pharmaceutical companies and accelerate the acquisition of new clients among the top 40 pharmaceutical companies through this event.

At this booth, the company will focus on showcasing its differentiated services, including: ▲ antibody-drug conjugate (ADC) production capabilities, ▲ the world's largest production capacity (784,000 liters), including its fifth plant (180,000 liters), and ▲ its contract development (CDO) platform. In particular, considering the rapidly growing Asian market, Samsung Biologics plans to highlight its advanced, one-stop contract development and manufacturing (CDMO) capabilities, including the ADC-dedicated production facility that began operations in March.

Additionally, on the first day of the event, October 8, Executive Vice President of Business Support James Choi and Executive Vice President of Sales & Operations Kevin Sharp will serve as speakers in a presentation session, explaining the company's CDMO competitiveness under the theme "Strategic Outsourcing for Supply Chain Resilience and Integrated Development and Manufacturing Services for Diverse Biopharmaceutical Modalities."

Meanwhile, Samsung Biologics is accelerating its efforts to target the Asian market by opening a sales office in Tokyo, Japan, earlier this year, following its office in the United States. In July, the company also participated in "Interphex Week Tokyo 2025," a comprehensive bio and pharmaceutical convention held in Tokyo, Japan, further strengthening its order acquisition activities among the top 40 pharmaceutical companies by expanding contact points with global and potential clients.

This content was produced with the assistance of AI translation services.